Associated Papers
Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.
Shah M et al.
Ebiomedicine, 2025
40562609 (PubMed )
Supplement: mmc10.xlsx › ANXA3_expression
Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.
Williams EA et al.
Neuro-oncology, 2023
37436963 (PubMed )
Supplement: noad121_suppl_supplementary_tables.xlsx › Table_S2
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › NF2
Prognostic impact of genetic alterations and methylation classes in meningioma.
Berghoff AS et al.
Brain Pathology (zurich, Switzerland), 2022
35213082 (PubMed )
Supplement: BPA-32-e12970-s001.xlsx › Sheet1
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Mansouri S et al.
Acta Neuropathologica, 2021
33025139 (PubMed )
Supplement: 401_2020_2230_MOESM1_ESM.pdf
Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.
Wallace AJ et al.
Genetic Testing, 2004
Select a paper to view details